Tender Offers and the Williams Act: Schedule TO, the 14D-9, and the Rules That Govern a Bid

Document type: Article Practice area: Corporate — Mergers and Acquisitions Jurisdiction: United States (federal securities law and Delaware) Last reviewed: 5 September 2026

Going around the board

Most acquisitions are negotiated. A buyer approaches a board, the board runs a process, the parties sign a merger agreement, and the stockholders vote.

A tender offer is different in one structurally important way: the bidder offers to buy shares directly from stockholders, and the board is not a party to the transaction. Stockholders decide individually whether to sell. A board that opposes the offer can recommend against it, and can deploy defenses, but it cannot simply refuse to let its stockholders sell their own property.

That is why the tender offer was, for a period, the instrument of hostile takeovers. And it is why Congress regulated it.

The Williams Act's actual purpose

Before 1968, a bidder could announce a cash tender offer on Monday, set it to expire Wednesday, and buy on a first-come-first-served basis. Stockholders faced a genuine prisoner's dilemma: tender immediately without information, or risk being left behind in a company controlled by a bidder who had already acquired what it wanted at a price you rejected.

The Williams Act, adding 15 U.S.C. § 78m(d) and § 78n(d)–(f) to the Exchange Act, addressed this with disclosure and process, not with substantive limits on who may bid. It requires bidders to disclose who they are, where the money comes from, and what they intend; it gives stockholders time; it lets them withdraw; and it requires pro rata treatment in a partial offer.

The statute is famously neutral between bidder and target. It was not enacted to make takeovers easier or harder, and courts have repeatedly refused to read it as favoring incumbents. Rondeau v. Mosinee Paper Corp., 422 U.S. 49 (1975) held that a target could not obtain an injunction for a late Schedule 13D filing absent irreparable harm, emphasizing that the Act protects investors rather than management. Piper v. Chris-Craft Industries, Inc., 430 U.S. 1 (1977) held that a defeated tender offeror has no implied private damages action under § 14(e) — the provision protects the target's stockholders, not disappointed bidders.

And Schreiber v. Burlington Northern, Inc., 472 U.S. 1 (1985) held that "manipulative" in § 14(e) requires deception, not merely conduct that affects the outcome. A bidder that withdrew one offer and substituted a lower negotiated one, with full disclosure, did not violate the Act even though stockholders were worse off. Full disclosure is the currency; unfairness alone is not a federal claim.

What is a tender offer?

Surprisingly, the statute does not define it. This matters, because the entire regulatory apparatus turns on the characterization, and open-market purchases and privately negotiated blocks are not subject to it.

Courts apply the eight-factor test from Wellman v. Dickinson, 475 F. Supp. 783 (S.D.N.Y. 1979):

Active and widespread solicitation of public stockholders;
Solicitation for a substantial percentage of the issuer's stock;
Offer at a premium over the prevailing market price;
Terms that are firm rather than negotiable;
Offer contingent on a fixed minimum number of shares tendered;
Offer open only for a limited time;
Offerees subjected to pressure to sell; and
Public announcements preceding or accompanying a rapid accumulation.

The Second Circuit refined this in Hanson Trust PLC v. SCM Corp., 774 F.2d 47 (2d Cir. 1985), holding that the Wellman factors are not a checklist to be mechanically totaled. The question is whether, absent the Williams Act's protections, there is a substantial risk that offerees will lack information needed to make a carefully considered appraisal. Purchases from five sophisticated institutions and one individual — none pressured, all informed — were not a tender offer even though they followed a terminated offer and quickly acquired 25% of the stock.

Practical consequences of the line:

Open-market accumulation is not a tender offer. A bidder may buy on the exchange up to any level, subject to Schedule 13D disclosure at 5%, antitrust notification, and any poison pill trigger.
Privately negotiated purchases from a handful of sophisticated holders are usually not a tender offer, per Hanson Trust.
A "creeping" acquisition conducted through many small purchases with public announcements and pressure can be recharacterized. The risk rises with the number of sellers, the presence of a deadline, and the sophistication gap.

The bidder's obligations

Schedule TO

A bidder for a class of equity registered under Section 12 must file a Schedule TO on the commencement date and deliver the offer materials to holders. The disclosure requirements, in 17 C.F.R. part 240, cover:

Identity and background of the bidder and its control persons, including criminal and securities-law history for the prior five years;
The terms — price, number of shares sought, expiration, withdrawal rights, proration, conditions;
Past contacts, transactions, and negotiations with the target;
The source and amount of funds, including financing arrangements and any conditions to them;
Purposes, plans, and proposals — including any plan for a merger, sale of assets, change in the board, delisting, or deregistration;
Interest in the target's securities, including transactions in the prior sixty days;
Persons retained — dealer-managers, information agents, depositaries, and their compensation.

The "plans and proposals" item deserves emphasis. A bidder that intends a back-end squeeze-out must say so. A bidder that says it is buying for investment and then launches a control bid has a disclosure problem, and the earlier statement will be an exhibit.

Timing and mechanics

Twenty business day minimum. The offer must remain open at least twenty business days from commencement.
Ten business days after certain changes. An increase or decrease in the consideration or the percentage sought requires the offer to remain open at least ten business days after notice.
Five business days for other material changes, as a general practice.
Withdrawal rights throughout the offering period.
Proration. In a partial offer that is oversubscribed, shares are purchased pro rata.
Prompt payment after expiration.
Subsequent offering period. A bidder may provide an additional period of three to twenty business days after accepting all tendered shares, during which stockholders may tender at the same price with no withdrawal rights and immediate payment. This is a practical tool for climbing to the 90% threshold for a short-form merger.

The all holders and best price rules

Two substantive constraints:

All holders. The offer must be open to all holders of the class. A bidder cannot exclude stockholders it dislikes, and cannot exclude foreign holders without careful structuring.

Best price. All holders must receive the highest consideration paid to any holder in the offer. The historical difficulty was that compensation arrangements with target executives — severance, retention bonuses, equity acceleration — were attacked as disguised additional consideration for their shares. The rule now contains a safe harbor for employment compensation, severance, and other employee benefit arrangements approved by independent directors, which resolved most of this litigation. Use the safe harbor deliberately: have the compensation committee or independent directors approve the arrangements and document that the approval was for services, not for shares.

Exchange offers

Where the consideration is securities, the offer is also an offer of securities requiring registration under the Securities Act, or an exemption. This adds a registration statement, prospectus delivery, and — critically — SEC review that can extend the timetable substantially. Bidders can commence an exchange offer before effectiveness under early-commencement rules, but cannot purchase until the registration statement is effective.

The target's obligations and choices

Schedule 14D-9

Within ten business days after the offer commences, the target must file and distribute a Schedule 14D-9 stating its position: recommend acceptance, recommend rejection, express no opinion and remain neutral, or state that it is unable to take a position. It must give the reasons.

The 14D-9 must also disclose:

Conflicts of interest — every agreement, arrangement, or understanding between the target or its affiliates and its executive officers, directors, or affiliates relating to the offer. This includes severance, retention, acceleration of equity, and any indemnification arrangements.
The "golden parachute" compensation payable in connection with the transaction, in tabular form, in a negotiated offer.
Any solicitation or recommendation the target is making.
Whether any negotiation is underway in response to the offer — with the ability to withhold specifics where disclosure would jeopardize the negotiation.
The financial adviser's opinion and analyses, in a negotiated deal.

Before the 14D-9 is filed, the target may not solicit or recommend acceptance or rejection; it may only advise stockholders to take no action pending its statement. A CEO who tells the press the offer is "grossly inadequate" before the 14D-9 is filed has created a problem.

The board's substantive duty

Federal law governs disclosure; state law governs whether the board may resist. In Delaware, a board's response to a takeover threat is reviewed under the enhanced scrutiny of Unocal Corp. v. Mesa Petroleum Co., 493 A.2d 946 (Del. 1985). The board must show:

Reasonable grounds for believing a danger to corporate policy and effectiveness existed — satisfied by showing good faith and reasonable investigation, materially enhanced by approval of a board with a majority of outside directors; and
That the response was reasonable in relation to the threat posed — which later cases refined to mean the response must not be coercive or preclusive, and must fall within a range of reasonable responses.

The poison pill

Moran v. Household International, Inc., 500 A.2d 1346 (Del. 1985) upheld the shareholder rights plan as a valid exercise of board authority, adopted before any specific threat, subject to Unocal review when actually used.

How it works. Each share carries a right. If any person acquires more than a threshold percentage — historically 15% or 20%, and as low as 4.9% for plans protecting net operating losses — the rights held by everyone except the acquirer become exercisable to purchase stock at a steep discount. The acquirer's stake is massively diluted. No pill has ever been triggered deliberately, because the economics are ruinous.

What the pill actually does. It does not prevent an acquisition. It forces the bidder to negotiate with the board, because only the board can redeem the rights. The bidder's answer is the proxy contest: run a slate of directors who will redeem the pill, and combine it with a tender offer conditioned on redemption. This is why the pill's real effect is to convert a two-month tender offer into a twelve-month campaign ending at the annual meeting.

What weakens a pill. Annual elections rather than a staggered board, because a bidder can replace the whole board at once. The absence of an advance notice bylaw with meaningful lead time. A stockholder base receptive to an activist. And proxy advisory firm policies that disfavor pills adopted without a stockholder vote.

What strengthens it. A classified board — although these have largely disappeared at large public companies. A low trigger. A restriction on stockholders' ability to call special meetings or act by written consent.

Air Products and Chemicals, Inc. v. Airgas, Inc., 16 A.3d 48 (Del. Ch. 2011) is the doctrinal endpoint. Airgas's board, having lost a proxy contest that installed three Air Products nominees, refused to redeem its pill against an all-cash, all-shares, fully financed offer that had been outstanding for over a year, on the ground that the price was inadequate. The Court of Chancery, plainly uncomfortable, upheld the refusal — the board was independent, well advised, and acting in good faith on a substantive view of value, and Delaware law did not authorize the court to substitute its judgment. Air Products withdrew.

Airgas establishes that a well-advised, independent board may "just say no" essentially indefinitely, provided its process is sound. That is a significant statement about who decides.

Insider trading in the tender offer context

Ordinary insider trading law requires a breach of a duty. Chiarella v. United States, 445 U.S. 222 (1980) reversed the conviction of a financial printer who deduced target identities from documents and traded, because he owed no duty to the sellers. United States v. O'Hagan, 521 U.S. 642 (1997) endorsed the misappropriation theory — a person who trades on confidential information in breach of a duty to the source violates § 10(b), even without a duty to the counterparty.

Rule 14e-3 is different and much broader. Once a substantial step toward a tender offer has been taken, any person in possession of material non-public information relating to the offer, who knows or has reason to know it came from the bidder, the target, or their agents, may not trade — without any showing of a breach of duty. O'Hagan upheld the rule as a valid prophylactic exercise of the Commission's authority under § 14(e).

Practical consequences. In a tender offer, the government does not have to prove a fiduciary breach. Everyone who touches the deal — bankers, lawyers, printers, dealer-managers, information agents, and their families — is exposed on possession alone. Trading windows and information barriers should be tightened the moment a tender offer becomes a live possibility, and the "substantial step" trigger is early: retaining a dealer-manager, arranging financing, or board authorization can suffice.

State regulation and its constitutional limits

States tried to protect local corporations from hostile bids, and the Supreme Court drew a line.

Edgar v. MITE Corp., 457 U.S. 624 (1982) struck down an Illinois statute requiring pre-offer notification and state review of an offer's substantive fairness. The statute applied to offers for companies with limited Illinois connections, imposed indefinite delay, and effectively let a state administrator block an offer — an impermissible burden on interstate commerce.

CTS Corp. v. Dynamics Corp. of America, 481 U.S. 69 (1987) upheld Indiana's control share acquisition statute, which stripped voting rights from shares acquired above thresholds unless restored by a vote of disinterested stockholders. The distinction mattered: the statute applied only to Indiana corporations, regulated the internal affairs of corporations the state had chartered, and gave the decision to stockholders rather than to a regulator.

The resulting landscape. States regulate takeovers through corporate law — business combination statutes imposing moratoria on mergers with interested stockholders, control share statutes, fair price statutes, and constituency statutes permitting boards to consider non-stockholder interests. Delaware's business combination statute prohibits a merger with a 15% stockholder for three years absent board approval before the acquirer crossed the threshold, approval by the board plus a supermajority of disinterested holders, or the acquirer reaching 85% in the transaction that crossed the threshold.

The two-step structure that revived the tender offer

For years, the tender offer's advantage — speed — was undercut by the back end. A bidder that acquired, say, 78% still needed a stockholder vote to squeeze out the rest, which meant a proxy statement, SEC review, and two months.

Delaware's Section 251(h) changed this. Where a merger agreement so provides, and the acquirer's tender offer results in ownership of at least the percentage of stock that would be required to adopt the merger (typically a majority), the back-end merger may be effected immediately, without a stockholder vote. The conditions are that the offer be for all outstanding shares, that the merger agreement expressly provide for the structure, and that the back-end consideration be the same as the offer price.

The consequence is significant. A negotiated two-step transaction can close in about five weeks: twenty business days of offer, acceptance, and an immediate merger. A one-step merger with a proxy statement takes two to three months minimum. For friendly deals with no financing or regulatory delay, the two-step is simply faster, and the tender offer has become as much a tool of negotiated deals as of hostile ones.

The older mechanism — the top-up option, which let a bidder buy newly issued shares to reach 90% and use the short-form merger statute — has largely been superseded, though it remains relevant where 251(h) is unavailable and for foreign or non-Delaware targets.

Issuer tender offers and self-tenders

A company can make a tender offer for its own shares, and the rules differ in ways that matter.

Why issuers do it. To return capital more quickly than open-market repurchases permit; to buy a large block from a departing holder; to signal management's view of value; to change the capital structure by borrowing and shrinking equity; or, defensively, to take shares out of a hostile bidder's reach at a price that competes with the bid.

The regulatory overlay. Issuer tender offers are governed by Rule 13e-4, which imports much of the third-party framework — twenty business day minimum, withdrawal rights, proration, all holders, best price — and adds requirements reflecting the issuer's informational advantage. The issuer files a Schedule TO of its own, must disclose its purposes and any plans, and may not purchase outside the offer during it or for ten business days after.

The Dutch auction structure. Rather than a fixed price, the issuer specifies a range and invites holders to tender at prices within it. The issuer then determines the lowest price at which it can buy the number of shares sought and pays that price to everyone who tendered at or below it. This is efficient — it discovers the clearing price — and it is common in large repurchases.

Where issuer self-tenders become defensive. A company under attack can offer to buy a substantial minority of its own shares at a premium, financed with debt. Holders who prefer cash take it; the remaining shares represent a more leveraged company that is harder to acquire. Delaware courts review such defensive self-tenders under Unocal, and the historic practice of excluding the hostile bidder from participating — a discriminatory self-tender — has since been prohibited by the all holders rule.

A discipline for issuers. Because the issuer knows more than its stockholders, the disclosure obligation is real. An issuer that repurchases shares while sitting on material undisclosed positive information has a serious problem, and the 13e-4 disclosure requirements are designed to surface exactly that. Confirm the company is not in possession of material non-public information before commencing, or disclose it.

Mini-tender offers and the abuse at the margin

A mini-tender offer is an offer for less than 5% of a class. Because it stays below the threshold that triggers Section 14(d), the bidder need not file a Schedule TO, need not provide the disclosure package, and need not comply with much of the framework — although the antifraud provision of § 14(e) still applies.

Legitimate mini-tenders exist. But the structure has been used abusively: an offer at a discount to the market price, sent to retail holders in a package resembling official corporate correspondence, in the expectation that some holders will tender without checking the current price. The Commission has warned investors repeatedly, and targets frequently respond with a public statement urging holders to check the market price.

What a target should do when a mini-tender arrives. Issue a prompt press release stating the offer price, the current market price, and that the board recommends holders review both. There is generally no 14D-9 obligation for an offer below the Section 14(d) threshold, but a public statement is prudent and costs nothing.

Litigation in and around tender offers

Tender offers generate litigation on a predictable schedule, and knowing what will be filed helps both sides prepare.

Disclosure suits. The most common. Plaintiffs allege the Schedule TO or the 14D-9 omitted material facts — most often the financial adviser's underlying analyses, management projections, the adviser's conflicts, or the details of insiders' compensation arrangements. These suits are usually filed within days of the 14D-9, seek an injunction against the expiration of the offer, and resolve through supplemental disclosure. The practical response is to make the initial disclosure thorough enough that the supplement is short.

Fiduciary duty suits. Where the board recommends acceptance, plaintiffs may allege the process was flawed or the price inadequate. Where the board recommends rejection and maintains a pill, the bidder or stockholders may sue under Unocal to compel redemption. The Airgas outcome makes the latter difficult but not impossible — a board that is not independent, not informed, or acting to entrench itself remains vulnerable.

Section 14(e) claims. Require deception under Schreiber; unfairness alone will not do. Note that a defeated bidder has no damages claim under Piper, which channels bidder grievances into injunctive relief and state-law theories.

Rule 14e-3 enforcement. Government actions, not private suits, and they arrive later — often years after the deal. Everyone involved in the transaction should understand that trading records will be reviewed.

Appraisal petitions. In the back-end merger, dissenting holders may seek appraisal. A stockholder who tendered has, of course, sold and has no claim; the petitions come from holders who neither tendered nor voted in favor. In a Section 251(h) transaction there is no vote at all, which raises its own questions about how the non-vote requirement is satisfied — the statute and practice have adapted, but the perfection mechanics deserve attention.

A note on timing. Because a tender offer can close in twenty business days, plaintiffs move for expedited proceedings almost immediately, and courts hold hearings on very compressed schedules. Both sides should have their disclosure record and their process record assembled before commencement, not after a complaint arrives.

A worked example: the Ferrand bid for Lindqvist Industrial

The players. Ferrand Group is a diversified industrial acquirer. Lindqvist Industrial makes precision bearings, trades at $28, has a market capitalization of $2.1 billion, an annually elected board, and a shareholder rights plan with a 15% trigger adopted three years ago.

Phase 1 — accumulation. Ferrand buys 4.7% on the open market over six weeks. It stops below 5% to avoid the Schedule 13D disclosure obligation, and well below the pill trigger. It files a premerger notification and observes the waiting period, because it intends to go further.

Phase 2 — the approach. Ferrand's chief executive, Adaeze Ferrand-Okoro, writes to Lindqvist's board proposing $37.00 per share in cash. The board, advised by counsel and bankers, responds after three weeks that the price substantially undervalues the company. Ferrand raises to $40.50. The board again declines and does not open its books.

Phase 3 — going public. Ferrand makes its letter public. Lindqvist's stock jumps to $39. Ferrand crosses 5% and files a Schedule 13D disclosing its stake, its purpose (to acquire control), and its proposals. The 13D is not optional and the "purpose" item must be accurate — Ferrand cannot describe an investment purpose while planning a bid.

Phase 4 — the offer. Ferrand commences a tender offer for all shares at $42.00 in cash, filing a Schedule TO with a fully committed financing package. Conditions: a minimum condition of a majority of shares on a fully diluted basis; redemption or invalidation of the rights plan; inapplicability of the business combination statute; antitrust clearance; and no material adverse change. The offer is open twenty business days.

Note what the conditions do. The pill condition and the business combination statute condition are what make this a bid the board can block. Ferrand cannot actually buy while the pill is outstanding — doing so would trigger catastrophic dilution — so the offer is, in substance, an invitation to the stockholders to pressure the board.

Phase 5 — the response. Within ten business days Lindqvist files a Schedule 14D-9 recommending rejection. It discloses its bankers' analyses supporting a higher standalone value, its directors' and officers' interests including change-of-control severance, and the fact that it has commenced a review of strategic alternatives. It does not redeem the pill.

Phase 6 — the proxy contest. Ferrand nominates a full slate for the annual meeting under Lindqvist's advance notice bylaw, which requires nominations ninety days before the anniversary of the prior meeting. Ferrand's counsel calendars this deadline the day the campaign begins, because missing it costs a year. It extends the tender offer, as bidders do, repeatedly.

Phase 7 — the market check. Under pressure, Lindqvist's board runs a process. Two private equity firms and one strategic look. One submits an indication at $44.00 subject to diligence. Ferrand raises to $45.50 and drops its financing condition.

Phase 8 — resolution. The board negotiates with Ferrand, obtains $47.25, and signs a merger agreement. The deal is restructured as a negotiated two-step: Ferrand amends its offer to the agreed price and adds a Section 251(h) provision, the board redeems the pill and approves the transaction for business combination statute purposes, and the 14D-9 is amended to recommend acceptance.

The offer expires with 81% tendered. Ferrand accepts, and the back-end merger is effected the same day under Section 251(h) without a vote. Elapsed time from the first public letter: nine months. Elapsed time from signing to closing: twenty-three business days.

What the case illustrates.

The pill did not stop the acquisition; it added nine months and $5.25 per share, which is a substantial return for the target's stockholders and a substantial argument for the defense.
The board's ability to "just say no" under Airgas was real, but the board chose not to test it at $47.25.
The proxy contest, not the tender offer, was the actual instrument of pressure.
The two-step structure made the last stage nearly instantaneous.

Conditions: the architecture of a bid

Conditions determine whether an offer is a real commitment or an option. Both sides read them first.

The minimum condition. Almost universal. It states the minimum number of shares that must be validly tendered and not withdrawn. In a negotiated two-step relying on Section 251(h), the minimum must be at least the percentage needed to adopt the merger — typically a majority of outstanding shares — and it should be measured on a fully diluted basis or with a clearly defined treatment of options, restricted stock units, and convertible securities. A vague minimum condition is a genuine problem: the bidder needs certainty about what it is buying and the target needs certainty about when the condition is satisfied.

Regulatory conditions. Expiry or termination of the antitrust waiting period; foreign competition clearances; sector-specific approvals; foreign investment screening where the bidder is non-US. These are ordinarily objective and non-waivable in substance, since the bidder cannot lawfully close without them.

The material adverse effect condition. The most negotiated. In a negotiated offer, it mirrors the merger agreement's MAE definition, with the familiar carve-outs for general economic conditions, industry conditions, changes in law and accounting, and the transaction's own announcement — usually subject to a disproportionate-effect qualifier. In a hostile offer, the bidder drafts it alone and typically drafts it broadly, which the target will attack as rendering the offer illusory.

Financing conditions. In a hostile bid, a financing condition is close to fatal to credibility, and sophisticated bidders eliminate it by obtaining committed financing before commencement. In a negotiated deal, the target will not sign without certain funds.

Pill and statute conditions. In a hostile offer, conditions requiring redemption of the rights plan and inapplicability of the business combination statute are what make the offer contingent on board action. They are honest about the reality: the bidder cannot close without the board's cooperation.

Impermissible conditions. A condition whose satisfaction is within the bidder's sole discretion can render the offer illusory and raises antifraud concerns. Conditions must be objectively determinable, and the bidder must exercise any waiver right reasonably and disclose it.

Waiver mechanics. Waiving a material condition may require the offer to remain open longer and may require dissemination of amended materials. Build the timetable to accommodate a waiver near expiration, because that is when waivers happen.

Cross-border tender offers

Where the target has non-US holders, or the bidder is non-US, additional structure is required.

The Tier I and Tier II exemptions provide relief from certain US requirements for offers for foreign private issuers where US ownership is limited, permitting the bidder to follow home-country practice in specified respects. Tier I applies where US holders own 10% or less and provides broad relief; Tier II applies up to 40% and provides narrower accommodations, including the ability to separate US and non-US offers, to pay on a delayed basis consistent with local practice, and to reconcile conflicting withdrawal-right regimes.

Excluding non-US holders. The all holders rule makes wholesale exclusion problematic, but offers routinely limit distribution of materials in jurisdictions where doing so would require registration or would violate local law, and structure participation accordingly. This requires careful drafting and local advice for each material jurisdiction.

Practical points. Confirm the target's US ownership percentage early, because it determines the available exemption and can require a look-through analysis of nominee holdings. Coordinate the timetable with any mandatory offer or squeeze-out regime in the target's home jurisdiction, which may impose different thresholds, prices, and deadlines. And confirm the tax treatment for holders in each jurisdiction, since the answer affects tender rates.

Practice notes

For bidders.

Decide early whether you are prepared to run a proxy contest. A tender offer against a pill is not a transaction; it is a first step in a campaign.
Calendar the advance notice deadline before anything else.
Make the financing airtight. A financing condition is the single easiest target for a board recommending rejection.
Say what you intend in the Schedule 13D and Schedule TO. Inconsistency between an early "investment purpose" and a later control bid is a durable liability.
Tighten information controls the moment a tender offer is contemplated. Rule 14e-3 does not require a breach of duty.
Use the subsequent offering period to climb toward thresholds.

For targets.

Have a rights plan on the shelf, not necessarily in force. Adoption can be same-day when needed, and an unadopted plan avoids the governance criticism.
Review the advance notice bylaw annually, and confirm it is enforceable and clearly drafted.
File the 14D-9 within ten business days, and say nothing substantive before it.
Disclose the conflicts. Severance, acceleration, and retention arrangements are the most-litigated omissions in 14D-9 practice.
Approve executive compensation arrangements through independent directors to secure the best-price safe harbor.
Run a real process if you are going to reject. Airgas protects a board that is independent, informed, and advised; it does not protect one that is entrenched and inattentive.

For stockholders.

Understand the withdrawal rights. Shares tendered may be withdrawn throughout the offering period, but not during a subsequent offering period.
Watch the minimum condition. An offer that fails its minimum condition buys nothing, and the tendered shares are returned.
Appraisal may be available in the back-end merger even where you tendered nothing — but the perfection requirements are strict and the timeline is short.

Choosing between a tender offer and a one-step merger

For a negotiated transaction, the choice is now genuinely open, and it turns on a small number of factors.

Speed favors the tender offer. With Section 251(h), a friendly two-step can close roughly twenty-three business days after signing. A one-step merger requires a proxy statement, potential SEC review, mailing, and a meeting — two to three months at best. Where the parties want certainty and the target's business is deteriorating or its employees are unsettled, five weeks beats twelve.

Regulatory delay erases the advantage. If antitrust clearance will take four months, the tender offer's speed is irrelevant; the transaction closes when the clearance arrives either way. A one-step merger runs the proxy process in parallel with the clearance process, at no cost in time. The tender offer's advantage exists only where nothing else is on the critical path.

Financing structure matters. Tender offers require funds available at expiration, which is soon and somewhat uncertain in timing. Debt financing sized to a tender offer must be available on a short fuse and remain available through extensions. Some financing structures — particularly those requiring a marketing period for a bond offering — fit a one-step timetable better.

Stockholder base matters. A tender offer succeeds if enough holders tender. Retail-heavy registers tender slowly, and a high minimum condition against a scattered base is a real risk. A concentrated institutional base tenders reliably. A one-step merger needs a vote, which has its own dynamics but does not require affirmative action from each holder — abstentions count against, which cuts the other way.

Securities consideration favors the one-step. An exchange offer requires a registration statement and prospectus delivery, and SEC review can be lengthy. If the consideration is stock, the timing advantage usually disappears.

Appraisal exposure differs. In a Section 251(h) transaction, holders who did not tender may seek appraisal, and the population of potential dissenters can be larger than in a one-step deal where many holders vote in favor. Model this if the target's register includes funds known to pursue appraisal.

A practical recommendation. Default to a one-step merger unless there is a specific reason for speed, and choose the tender offer where the transaction is all cash, fully financed, free of long-lead regulatory conditions, and the register is institutional. Draft the merger agreement to permit a switch — many now include a provision allowing the parties to convert from one structure to the other if circumstances change — so that a regulatory surprise does not strand the deal in the wrong format.